TY - JOUR
T1 - Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis
T2 - A multicenter prospective open-label study
AU - Matsumoto, Takayuki
AU - Andoh, Akira
AU - Okawa, Kiyotaka
AU - Ito, Hiroaki
AU - Torii, Ayao
AU - Yoshikawa, Syusaku
AU - Nakaoka, Ryosuke
AU - Okuyama, Yusuke
AU - Oshitani, Nobuhide
AU - Nishishita, Masakazu
AU - Watanabe, Kenji
AU - Fukunaga, Ken
AU - Ohnishi, Kunio
AU - Kusaka, Takeshi
AU - Yokoyama, Yoko
AU - Sasaki, Masaya
AU - Tsujikawa, Tomoyuki
AU - Aoki, Tetsuya
AU - Kusaka, Toshihiro
AU - Takeda, Yasuhiro
AU - Umehara, Yasushi
AU - Nakamura, Shiro
AU - Fujiyama, Yoshihide
PY - 2008/12
Y1 - 2008/12
N2 - Leukocytapheresis (LCAP) has been advocated as a treatment for moderate to severe active ulcerative colitis (UC) in Japan. To clarify the predictive factors for a rapid response to LCAP treatment, we conducted a multicenter prospective open-label study. A total of 105 patients with UC were analyzed. LCAP was performed using a Cellsorba EX column once a week for 5-10 sessions. The response was evaluated by the clinical activity index (CAI). When the CAI score decreased to less than half the pretreatment value or to less than 5 points within 3 weeks, the patient was considered to be a rapid responder. The average CAI significantly decreased from 11.7 to 4.2 (P < 0.01). Seventy-four percent of the patients responded to the therapy, and 53% of these patients were rapid responders. The following significant factors correlated with the rapid LCAP response: (i) steroid resistance (P < 0.05), (ii) severe disease indicated by a CAI score greater than 11 (P = 0.05), (iii) disease duration of less than 1 year (P < 0.05), and (iv) C-reactive protein levels before treatment (P < 0.01). These results suggest that the early initiation of LCAP is beneficial in patients with steroid-resistant UC.
AB - Leukocytapheresis (LCAP) has been advocated as a treatment for moderate to severe active ulcerative colitis (UC) in Japan. To clarify the predictive factors for a rapid response to LCAP treatment, we conducted a multicenter prospective open-label study. A total of 105 patients with UC were analyzed. LCAP was performed using a Cellsorba EX column once a week for 5-10 sessions. The response was evaluated by the clinical activity index (CAI). When the CAI score decreased to less than half the pretreatment value or to less than 5 points within 3 weeks, the patient was considered to be a rapid responder. The average CAI significantly decreased from 11.7 to 4.2 (P < 0.01). Seventy-four percent of the patients responded to the therapy, and 53% of these patients were rapid responders. The following significant factors correlated with the rapid LCAP response: (i) steroid resistance (P < 0.05), (ii) severe disease indicated by a CAI score greater than 11 (P = 0.05), (iii) disease duration of less than 1 year (P < 0.05), and (iv) C-reactive protein levels before treatment (P < 0.01). These results suggest that the early initiation of LCAP is beneficial in patients with steroid-resistant UC.
KW - Clinical activity index
KW - Leukocytapheresis
KW - Predictive factors
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=58149193446&partnerID=8YFLogxK
U2 - 10.1111/j.1744-9987.2008.00639.x
DO - 10.1111/j.1744-9987.2008.00639.x
M3 - 学術論文
C2 - 19140847
AN - SCOPUS:58149193446
SN - 1744-9979
VL - 12
SP - 484
EP - 490
JO - Therapeutic Apheresis and Dialysis
JF - Therapeutic Apheresis and Dialysis
IS - 6
ER -